Global Tuberculosis Vaccines Market Size By Type (Immunotherapeutic Vaccines, Booster Vaccines), By Application (Hospitals, Clinics), By Region, And Segment Forecasts, 2023 to 2032

The Global Tuberculosis Vaccines Market was valued at USD 120.4 million in 2023 and is projected to reach USD 279.7 million by 2031, growing at a CAGR of 11.1% during the forecast period from 2023 to 2031. The surge in demand is attributed to increasing global awareness about tuberculosis (TB), rising initiatives by governments and health organizations to eradicate TB, and the advancement in vaccine research and development. Emerging economies are witnessing a higher prevalence of TB, which is driving investments in preventive healthcare and accelerating the development of effective TB vaccines.

Drivers:

1. Global TB Elimination Programs:

Various international and national initiatives, such as the WHO’s End TB Strategy and funding by Gavi, are propelling demand for tuberculosis vaccines, particularly in high-burden countries.

2. Advancements in Vaccine Technology:

Progress in genetic engineering, adjuvant technology, and recombinant DNA approaches is enabling the development of more effective and safer TB vaccines.

3. Growing Healthcare Expenditure in Developing Regions:

Rising healthcare infrastructure investment, particularly in Asia and Africa, is supporting vaccination campaigns and improving access to immunization.

Restraints:

1. Complex Clinical Trial Process:

TB vaccines require large-scale, long-term efficacy trials, which are costly and time-consuming, delaying market entry for novel vaccines.

2. Limited Commercial Success of Existing Vaccines:

The BCG vaccine, although widely used, has variable efficacy, especially in adults. The lack of proven, widely accepted adult vaccines limits market growth potential.

Opportunity:

1. Growing Investment in R&D by Pharmaceutical Giants:

Pharma companies and public-private partnerships are increasing funding for next-generation TB vaccines, including subunit, viral vector, and mRNA-based candidates.

2. Expansion in High-Burden Regions:

Asia-Pacific and Sub-Saharan Africa represent significant market opportunities due to their high TB incidence and the prioritization of immunization in public health agendas.

Market by System Type Insights:

Based on vaccine type, the Subunit Vaccines segment held the largest market share in 2023. These vaccines are gaining traction due to their improved safety profiles and potential for higher efficacy compared to traditional BCG vaccines. The Viral Vector Vaccines segment is expected to register the fastest growth during the forecast period, supported by technological innovations and positive clinical trial outcomes.

Market by End-use Insights:

By end-use, the Public Health Sector segment dominated the market in 2023, accounting for the largest revenue share. Government-funded immunization programs and international aid initiatives contribute significantly to vaccine distribution in high-prevalence regions. The Private Healthcare Sector is anticipated to grow steadily due to increasing TB awareness among urban populations and rising demand for preventive healthcare services.

Market by Regional Insights:

Geographically, Asia-Pacific accounted for the largest share of the global tuberculosis vaccines market in 2023. Countries like India, China, and Indonesia exhibit high TB prevalence and robust government immunization efforts. Africa is projected to witness the highest CAGR through 2031, driven by growing international aid, expanded healthcare access, and rising investments in healthcare infrastructure.

Competitive Scenario:

Key players in the Global Tuberculosis Vaccines Market include Serum Institute of India Pvt. Ltd., Aeras, Sanofi Pasteur, GlaxoSmithKline plc, Statens Serum Institut, Biofabri, and Bharat Biotech. These companies are focused on collaborative R&D, clinical trials, and strategic licensing agreements. For instance:

In 2023, GSK and Aeras reported positive Phase IIb results for the M72/AS01E vaccine candidate, demonstrating over 50% efficacy in preventing pulmonary TB.

In 2024, the Serum Institute announced expansion plans for its TB vaccine production facility aimed at meeting growing demand across Africa and Southeast Asia.

Scope of Work – Global Tuberculosis Vaccines Market

Key Market Developments:

March 2023: The WHO included two new TB vaccines in its priority pipeline, increasing global funding and attention to advanced candidates.

September 2024: Biofabri partnered with African vaccine initiatives to supply their MTBVAC candidate for late-stage trials in Sub-Saharan Africa.

January 2025: Bharat Biotech launched a new production unit dedicated to scalable TB vaccine manufacturing to meet global demand.

FAQs:

1) What is the current market size of the Global Tuberculosis Vaccines Market?

The market was valued at USD 120.4 million in 2023.

2) What is the major growth driver of the Global Tuberculosis Vaccines Market?

Government-backed eradication programs and technological advancements in vaccine development.

3) Which is the largest region during the forecast period in the Global Tuberculosis Vaccines Market?

Asia-Pacific is the largest regional market, driven by high TB prevalence and public health initiatives.

4) Which segment accounted for the largest market share in the Global Tuberculosis Vaccines Market?

The Subunit Vaccines segment held the largest market share in 2023.

5) Who are the key market players in the Global Tuberculosis Vaccines Market?

Key players include Serum Institute of India, Aeras, GSK, Sanofi Pasteur, Biofabri, and Bharat Biotech.